These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29978754)

  • 1. Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.
    Taneja A; Jones J; Pittaluga S; Maric I; Farooqui M; Ahn IE; Wiestner A; Sun C
    Leuk Lymphoma; 2019 Feb; 60(2):519-522. PubMed ID: 29978754
    [No Abstract]   [Full Text] [Related]  

  • 2. BTK/PD-1 blockade for treatment of Richter's transformation.
    Tang PS; Tam CS
    Lancet Haematol; 2019 Feb; 6(2):e59-e60. PubMed ID: 30642820
    [No Abstract]   [Full Text] [Related]  

  • 3. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Tam CS
    Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
    [No Abstract]   [Full Text] [Related]  

  • 4. Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia.
    Glavey S; Quinn J; McCloy M; Sargent J; McCartney Y; Catherwood M; Marafioti T; Leader M; Murphy P; Thornton P
    Eur J Haematol; 2017 Oct; 99(4):378-380. PubMed ID: 28561533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia.
    Furman RR; Luan Y; Bilotti E; Graef T
    Leuk Lymphoma; 2017 Jun; 58(6):1502-1505. PubMed ID: 27784188
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term follow-up and future direction on the management of chronic lymphocytic leukemia/small lymphocytic leukemia.
    Hanna KS; Fijalka A; Watson I; Brown O; Ojulu A
    J Oncol Pharm Pract; 2022 Dec; 28(8):1869-1884. PubMed ID: 35635742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
    Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acalabrutinib: First Global Approval.
    Markham A; Dhillon S
    Drugs; 2018 Jan; 78(1):139-145. PubMed ID: 29209955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
    Cervantes-Gomez F; Kumar Patel V; Bose P; Keating MJ; Gandhi V
    Leukemia; 2016 Aug; 30(8):1803-4. PubMed ID: 27198052
    [No Abstract]   [Full Text] [Related]  

  • 10. Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
    Varma G; Johnson TP; Advani RH
    Clin Adv Hematol Oncol; 2016 Jul; 14(7):543-54. PubMed ID: 27379948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-cell receptor inhibitors in chronic lymphocytic leukemia.
    Flinn IW
    Clin Adv Hematol Oncol; 2011 Aug; 9(8):605-6. PubMed ID: 22236988
    [No Abstract]   [Full Text] [Related]  

  • 12. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.
    Winer ES; Ingham RR; Castillo JJ
    Expert Opin Investig Drugs; 2012 Mar; 21(3):355-61. PubMed ID: 22300471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CLL in focus: news in the treatment of chronic lymphocytic leukemia.
    Schuyler D
    Clin Adv Hematol Oncol; 2020 Oct; 18(10):627-628. PubMed ID: 33201868
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    Pineda-Gayoso R; Alomar M; Lee DH; Fradley MG
    Curr Treat Options Oncol; 2020 Jun; 21(8):67. PubMed ID: 32607825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Tran PN; O'Brien S
    Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.
    Barrientos J; Rai K
    Leuk Lymphoma; 2013 Aug; 54(8):1817-20. PubMed ID: 23617325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.
    Lucas F; Woyach JA
    Target Oncol; 2019 Apr; 14(2):125-138. PubMed ID: 30927175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hodgkin Lymphoma Transformation of Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: Chance Association or Therapy-related?
    Sachanas S; Pangalis GA; Moschogiannis M; Yiakoumis X; Koulieris E; Tsirkinidis P; Kalpadakis C; Rontogianni D
    Anticancer Res; 2017 Jun; 37(6):3277-3280. PubMed ID: 28551676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib in B lymphoid malignancies.
    Smith MR
    Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Marostica E; Sukbuntherng J; Loury D; de Jong J; de Trixhe XW; Vermeulen A; De Nicolao G; O'Brien S; Byrd JC; Advani R; McGreivy J; Poggesi I
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):111-21. PubMed ID: 25381051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.